Find Drugs for Infections and Infectious Diseases in Phase I Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): UB-612

            Therapeutic Area: Infections and Infectious Diseases Product Name: UB-612

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: University of Nebraska Medical Center

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 11, 2020

            Details:

            With respect to the COVID-19 pandemic, UNMC trials will focus preliminarily on conducting Phase I/II human trials in the United States of COVAXX's UB-612 vaccine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Transcrocetinate sodium

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 10, 2020

            Details:

            The Phase 1b study trial will be a randomized, placebo-controlled safety and efficacy study of TSC in hospitalized COVID-19 patients that will be conducted in the United States and Europe after consultation with, and approval from, local regulatory authorities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aspartyl-alanyl-diketopiperazine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 09, 2020

            Details:

            Ampion-treated patients showed improvement from severe disease/hospitalization to uninfected/ambulatory on the ordinal scale.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PLG0206

            Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 09, 2020

            Details:

            PLG0206 is the first novel anti-infective to be granted Orphan Drug Designation, confirmation that we are advancing a meaningful therapy that can address an unmet medical need, beginning with PJI.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aspartyl-alanyl-diketopiperazine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 04, 2020

            Details:

            Enrollment has been completed for the AmpionTM Phase I US based clinical trial for IV treatment of COVID-19 patients requiring supplemental oxygen.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SAB-185

            Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-185

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 02, 2020

            Details:

            Sanford Health initiated a Phase 1b trial of SAB-185, a first-of-its-kind human polyclonal antibody therapeutic candidate developed by SAB Biotherapeutics (SAB), that would be used to treat patients with mild to moderate COVID-19 at an early stage of the disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LMN-101

            Therapeutic Area: Infections and Infectious Diseases Product Name: LMN-101

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: WestRiver Management

            Deal Size: $16.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing September 01, 2020

            Details:

            The round brings Lumen’s total equity and non-dilutive investment to $68 million and will support continued advancement of Lumen’s three clinical programs for C. difficile, norovirus and traveler’s diarrhea.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-2173

            Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-2173

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 01, 2020

            Details:

            ATI-2173 showed good oral bioavailability with liver targeting in rat and cynomolgus monkey studies, leading to reduced systemic plasma and skeletal muscle exposure while still maintaining effective concentrations of the active 5’-triphosphate in the liver.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NTX-1175

            Therapeutic Area: Infections and Infectious Diseases Product Name: NOC-100

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 01, 2020

            Details:

            First subject in a healthy volunteer Phase 1 trial of NOC-100, an inhaled formulation of NTX-1175. NTX-1175 is a novel small molecule Charged Sodium Channel Blocker (“CSCB”) being developed for cough.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-301

            Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 01, 2020

            Details:

            The Phase 1 study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.

            PharmaCompass